# Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

> **NCT01437397** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1692 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Aclidinium Bromide/Formoterol Fumarate
- **DRUG:** Aclidinium Bromide/Formoterol Fumarate
- **DRUG:** Aclidinium Bromide
- **DRUG:** Formoterol Fumarate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01437397
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 1692 (ACTUAL)
- **Last updated:** 2017-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01437397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01437397, "Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01437397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*